Exenatide, a therapeutic agent classified as a glucagon-like peptide 1 agonist and traditionally employed for type 2 diabetes, has recently demonstrated potential positive impacts on motor functionalities in a controlled trial involving Parkinson’s disease patients. The gene discussed is GCG; the disease is Parkinson disease.